权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

CELL-FREE REGENERATIVE MEDICINE: Nano-Engineered "LIFNano" to treat Multiple Sclerosis

无细胞再生医学：纳米工程“LIFNano”治疗多发性硬化症

基本信息

批准号：
102847
负责人：
金额：
$ 105.58万
依托单位：
LIF NANO RX LTD
依托单位国家：
英国
项目类别：
Collaborative R&D
财政年份：
2017
资助国家：
英国
起止时间：
2017 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=102847
关键词：
CELL FREE REGENERATIVE MEDICINE Nano

项目摘要

NANOMEDICINE (NanoMed) is a new era in medicine that exploits nano-engineering to deliver the right dose of therapy to the right place, at the right time. LIF is a growth factor important for maintaining brain health and the SME "LNT" has pioneered NanoMed for delivery of LIF as a revolutionary approach to treat the devastating autoimmune disease MULTIPLE SCLEROSIS (MS). Incurable, MS attacks the brain, starting in young adulthood and costing the global economy some $100bn pa. AIMS: having proven LIFNano (LN001) is far superior to the best alternative therapy for MS, this project will now deliver LN001 to patients on two fronts: (i) by establishing the first UK-based commercial resource for NanoMed; and (ii) by securing LN001 in a clinical formula. Three levels of synergy operate: UK manufacture, UK intellectual property with worldwide exclusive licence to LNT, and UK-based global leader in new therapeutic approaches to MS. The gain to the UK economy will be high and the added value of I-UK support to LNT will exceed 100-fold on licencing as Big Pharma become engaged especially since LN001 is applicable to a wide range of degenerative conditions. Further added value is in the increased specialist portfolio of UK's High Value Manufacturing Catapult (CPI).

纳米医学（NanoMed）是医学的一个新时代，它利用纳米工程在正确的时间向正确的地点提供正确剂量的治疗。LIF是一种对维持大脑健康很重要的生长因子，SME“LNT”开创了NanoMed，将LIF作为治疗毁灭性自身免疫性疾病多发性硬化症（MS）的革命性方法。多发性硬化症无法治愈，它从年轻人开始攻击大脑，每年给全球经济造成约1000亿美元的损失。目标：已经证明LIFNano（LN 001）远远上级MS的最佳替代疗法，该项目现在将在两个方面向患者提供LN 001：（i）通过建立第一个基于英国的NanoMed商业资源;（ii）通过将LN 001固定在临床配方中。三个层次的协同作用运作：英国制造，英国知识产权与全球独家许可LNT，和英国的全球领导者在新的治疗方法，以MS的收益将是英国经济和增加值的I-UK支持LNT将超过100倍的许可，因为大制药公司成为从事特别是因为LN 001适用于广泛的退行性疾病。进一步的附加值是在英国的高价值制造弹射器（CPI）的专业组合增加。